Clinical trial NCT01262014: Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Official title: Phase II, Multicenter, Prospective, Single Arm, Open Labeled Clinical Trial Investigating Pazopanib, a Multi-targeted Tyrosine Kinase Inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit in Patients With Platinum-resistant Advanced Ovarian Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Platinum-resistant Advanced Ovarian Cancer
Keywords: platinum
resistant
advanced
ovarian
cancer
Lead sponsor: Grupo Español de Investigación en Cáncer de Ovario
Sponsor class: OTHER
First posted: 2010-12-17
Enrollment: 28
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Given the low Responses Rates and short survival times achieved with conventional cytotoxic agents in resistant ovarian cancer patients, new treatment options are needed in this patient population.Antiangiogenic therapy has an important role in this group of patients and Pazopanib in particular. We are going to study if Pazopanib is able to control disease-related symptoms minimizing the side effects of treatment. This aspect is very important in the treatment of resistant ovarian cancer patient since our treatment is palliative without any impact in overall survival. So our goal is to study the Clinical Benefit Rate (objective responses plus stable disease rates) achieved with Pazopanib and its toxicity profile in this subgroup of patients

Detailed description: Ovarian cancer is considered a chemo-responsive neoplasm, with initial response rates to systemic chemotherapy exceeding 80% when integrated with primary cytoreductive surgery Despite this, over 50% of women diagnosed with epithelial ovarian cancer eventually go on to die from their disease. Six major trials published over the past 15 years report that the median PFS for patients with advanced disease ranges between 16 and 23 months while the median OS lies between 31 and 65 months.The majority of patients who achieve a Complete Response with first-line chemotherapy ultimately develop recurrent disease. These patients can be subdivided into platinum-sensitive or platinum-resistant groups. In platinum-sensitive patients, disease recurrence occurs more than 6 months after cessation of initial platinum-containing chemotherapy. Platinum-based therapies are typically used to retreat these patients, in light of clinically meaningful responses observed in these patients following a second platinum-based treatment.Currently, there is no optimal treatment strategy for platinum-resistant patients whose disease recurs within 6 months of completing initial platinum-based chemotherapy.Despite a wide range of available treatments, prolonged survival has not been shown in this setting, and ORR is generally less than 20%. As resistant-disease is not curable, the goals of treatment for these patients include palliation of symptoms and improvements in quality of life. Platinum-resistance is therefore a significant clinical problem for which improved treatment regimens are needed. In this regard, molecular targeted therapeutic agents herald a new era for cancer treatment. In the setting of epithelial ovarian cancer, a growing body of evidence supports the use of anti-angiogenic agents.Platinum-resistant ovarian cancer patients are often treated with sequential lines of single-agent chemotherapy. Commonly used agents include topotecan, pegylated liposomal doxorubicin (PLD), weekly paclitaxel and gemcitabine.Topotecan is topoisomerase I inhibitor well established as therapy for recurrent ovarian cancer, with demonstrated efficacy in platinum-resistant populations. PLD is licensed in the US and Europe for use in ovarian cancer after failure of platinum chemotherapy and is recommended by the NCCN as a treatment option in this setting. PLD and topotecan have been compared in a Phase III study of 474 patients with tumours that were recurrent or refractory to platinum-based chemotherapy. In the subgroup of patients with platinum-resistant tumours treated with PLD (n=130), the ORR was 12.3%, and median PFS and OS were 2.1 and 8.2 months, respectively. The 124 platinum-resistant patients who received topotecan achieved median PFS and OS of 3.1 months and 9.5 months, respectively, which were not significantly different from the PLD group. For platinum-resistant patients, outcomes were not significantly different between treatment groups so whatever treatment option is acceptable.In a recent study in platinum-resistant recurrent ovarian cancer patients, topotecan monotherapy showed and ORR of 19% and 9% when used as conventional or weekly schedule, respectively. Angiogenesis is known to play a critical role in the growth of ovarian tumours and may represent an important target. For example, several studies have demonstrated that increased microvessel density in primary ovarian tumours is associated with VEGF expression and predicted worsened survival rates. Likewise, circulating VEGF levels were significantly higher in ovarian cancer subjects with an advanced stage at diagnosis, poorly-differentiated tumours, or increased levels of ascites as compared to subjects with an early stage, well-differentiated tumour(s), and less ascites. Tumour-derived VEGF may play a role in ascites formation. Angiogenesis has been shown to be a negative predictive factor for overall survival and disease-free survival in women with advanced ovarian cancer 18. Blockade or inhibition of VEGF (eg, using bevacizumab) or VEGFR (using TKIs) have been shown to be effective in Phase II studies in ovarian cancer. For example, single-agent bevacizumab has shown a 16-21% overall tumour response rate (ORR) in two studies of previously treated patients with ovarian cancer.Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit. Pazopanib has shown evidence of antitumor activity in clinical studies of ovarian cancer. VEG104450 is a Phase II study of pazopanib in subjects with ovarian, fallopian tube, or primary peritoneal cancers who had responded to first-line chemotherapy and who were at high risk of clinical recurrence (as evidenced by rising CA-125 levels). 36 subjects were enrolled, of which 22 (61%) had a sensitive platinum relapse and a previous chemotherapy regimen. Final results obtained recently indicate the following:10 out of 36 (28%) subjects experienced a CA-125 response to pazopanib with responses occurring shortly after start of pazopanib administration (median time to response 29 days) with a median duration of response of 113 days 21.Taking into account theses results, pazopanib is one of the promising antiangiogenic therapies to be studied against ovarian cancer

Eligibility criteria: Inclusion Criteria:

1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.
2. Age ≥ 18 years
3. The patient has histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, fallopian tube cancer
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
5. The patient has completed at least 4 CYCLES OF one and up to two platinum-containing regimens (involving cisplatin or carboplatin),for the management of this condition. Treatment may have included intraperitoneal therapy, consolidation or extended therapy administered after surgical or nonsurgical assessment.
6. The patient must have a platinum-free interval of ≤ 6 months after the final dose of primary or subsequent platinum-based therapy.

   Patients must have platinum-resistant disease,(defined as progression within \<6 months from completion of a minimum of 4 platinum therapy cycles. The date should be calculated from the last administered dose of platinum therapy.
7. The patient has at least one unidimensionally measurable target lesion (≥ 20 mm or ≥ 10 mm by spiral computed tomography \[CT\] or magnetic resonance imaging \[MRI\]), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines V 1.1.
8. Previously archived tumor tissue from either the primary or metastatic tumor (paraffin block or 10 unstained slides) should be collected prior to administration of the first dose of study therapy and stored at a secure central laboratory.
9. Adequate organ system function
10. Women of child bearing potential should be using an effective method of contraception (complete abstinence, any intrauterine device (IUD) with published data showing that the lowest expected failure rate is \< 1 % per year; or any other methods with published data showing that the lowest expected failure rate is less than 1 % per year) before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative test serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta human chorionic gonadotropin \[β-HCG\]) within 7 days prior to randomization.
11. Able to swallow oral compound.
12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria:

1. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
2. Previous treatment with \>2 anticancer regimens for ovarian cancer
3. Prior treatment with any antiangiogenic treatment (i.e. Bevacizumab)
4. Patients with platinum-refractory disease defined as those patients progress during platinum-based therapy.
5. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. Screening with CNS imaging studies (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) is required only if clinically indicated or if the subject has a history of CNS metastases.
6. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:

   * Active peptic ulcer disease
   * Known intraluminal metastatic lesion/s with risk of bleeding
   * Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other gastrointestinal conditions with increased risk of perforation
   * History of bowel obstruction, including sub-occlusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment.

     * active episodes of intestinal pseudo-obstruction
7. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:

   * Malabsorption syndrome
   * Major resection of the stomach or small bowel.
   * Grade 3 diarrhoea
8. Presence of uncontrolled infection.
9. Corrected QT interval (QTc) \> 480 msecs using Bazett's formula
10. History of any one or more of the following cardiovascular conditions within the past 6 months:

    * Cardiac angioplasty or stenting
    * Myocardial infarction
    * Unstable angina
    * Coronary artery bypass graft surgery
    * Symptomatic peripheral vascular disease
    * Class II, III or IV congestive heart failure, as defined by the New York Heart Association (NYHA
11. Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg\] instead an anti-hypertensive treatment.

    Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be assessed using the following recommendations:

    Once a patient has had an elevated blood pressure reading (\> 140/80mmHg) this should be confirmed with another measurement, done locally if possible, either by the patients local doctor, or by home monitoring if available. Patients should continue to have their blood pressure monitored, at least weekly, until it becomes controlled (i.e. ≤ 140/80mmHg on 2 separate occasions, at least one week apart). Anti-hypertension medication changes, such as initiation of therapy, dose increases of existing therapies, or addition of other anti-hypertensive agents, should be done if the blood pressure remains high at 2 consecutive readings, at least 24 hours apart. Please, refer to guidance regarding the management of hypertension for the patient's local doctor for further information.
12. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

    Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
13. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
14. Prior minor surgery within 7 days prior to first dose of study drug
15. Evidence of active bleeding or bleeding diathesis.
16. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
17. Hemoptysis within 6 weeks of first dose of study drug.
18. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
19. Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
20. Treatment with any of the following anti-cancer therapies:

    radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
21. Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.
22. Women who are pregnant or breast-feeding

Primary outcomes:
measure: The primary efficacy endpoint for this study is Clinical Benefit Rate
timeFrame: average 30 months
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: average 30 months
measure: Biological Response by CA-125 (GCIG Criteria)
timeFrame: average 30 months
measure: Overall Survival (OS)
timeFrame: Average 3 years
measure: Biological progression-free interval (PFIBIO)
timeFrame: average 30 months
measure: Quality of Life and symptom control
timeFrame: average 5 years
measure: The safety and tolerability of study drug
timeFrame: Average 5 years
measure: Descriptive pharmacodynamic profile
timeFrame: 30 months
Other outcomes:
Locations:
city: Alcorcón
country: Spain
facility: H. Alcorcón
city: Barcelona
country: Spain
facility: H. de la Santa Creu i Sant Pau
city: Barcelona
country: Spain
facility: H Vall d'Hebron
city: Barcelona
country: Spain
facility: H. Clínic Barcelona
city: Cordoba
country: Spain
facility: H Reina Sofía Cordoba
city: Hospitalet de LLobregat
country: Spain
facility: Intitut Català d' Oncolgia L' Hospitalet
city: Madrid
country: Spain
facility: HGU Gregorio Marañón
city: Madrid
country: Spain
facility: Centro Oncológico MD Anderson Spain
city: Madrid
country: Spain
facility: H Ramón y Cajal de Madrid
city: Madrid
country: Spain
facility: H Madrid. Centro Integral Oncológico Clara Campal
city: Manresa
country: Spain
facility: H de Sant Joan de Deu
city: Murcia
country: Spain
facility: H Morales Meseguer
city: Palma de Mallorca
country: Spain
facility: H Son Dureta
city: Palma de Mallorca
country: Spain
facility: H Son Llatzer
city: Sabadell
country: Spain
facility: H. Parc Taulí
city: Santander
country: Spain
facility: H Marqués de Valdecilla
city: Valencia
country: Spain
facility: H La Fe de Valencia
city: Valencia
country: Spain
facility: Instituto Valenciano de Oncología
city: Valencia
country: Spain
facility: H General de Valencia
city: Zaragoza
country: Spain
facility: H Miguel Servet
Study officials:
affiliation: H Vall d'Hebron
name: Ana Oaknin, MD
role: STUDY_CHAIR
References: